Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
400
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pivotal Research Centers
Peoria, Arizona, United States
21st Century Neurology
Phoenix, Arizona, United States
Margolin Brain Institute
Fresno, California, United States
Pharmacology Research Institute
Northridge, California, United States
UCI Medical Center
Orange, California, United States
Pacific Research Network
San Diego, California, United States
Affiliated Research Institute
San Diego, California, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Baumel-Eisner Neuromedical Institute
Fort Lauderdale, Florida, United States
...and 24 more locations